Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth A Jacobson

Showing results (481-490 of 599) with videos related to

Pageof 60
Sort By:
Communications Biology|November 22, 2025
UDP-glucose and MRS2905 agonist-bound states of the purinergic P2Y<sub>14</sub> receptorJonathan F Fay, Joseph Kousouros, Zhan-Guo Gao, et al.
European Journal of Medicinal Chemistry|September 26, 2025
(N)-Methanocarba-adenosines as monoamine transporter allosteric inhibitors: Extended N<sup>6</sup> groups for bitopic stabilizationDilip K Tosh, Matteo Pavan, Laura B Kozell, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 12, 2004
Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cellsMeera Srivastava, Ofer Eidelman, Jian Zhang, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 5, 2010
Treatment of heart failure by a methanocarba derivative of adenosine monophosphate: implication for a role of cardiac purinergic P2X receptorsSi-Yuan Zhou, Mohammed Mamdani, Khaled Qanud, et al.
Journal of Medicinal Chemistry|June 23, 2016
Structure-Based Design of 3-(4-Aryl-1H-1,2,3-triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor AntagonistsAnna Junker, Ramachandran Balasubramanian, Antonella Ciancetta, et al.
Journal of Medicinal Chemistry|August 9, 2002
Synthesis, biological properties, and molecular modeling investigation of the first potent, selective, and water-soluble human A(3) adenosine receptor antagonistAnna Maconi, Giorgia Pastorin, Tatiana Da Ros, et al.
Molecular Pharmacology|September 18, 2009
Quantification of Gi-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of the human P2Y14 receptorRhonda L Carter, Ingrid P Fricks, Matthew O Barrett, et al.
Journal of the American Chemical Society|December 16, 2024
Photoswitchable Diazocine Derivative for Adenosine A<sub>3</sub> Receptor Activation in PsoriasisMarc López-Cano, Mirko Scortichini, Dilip K Tosh, et al.
Journal of Medicinal Chemistry|January 5, 2002
Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptorsHak Sung Kim, R Gnana Ravi, Victor E Marquez, et al.
Scientific Reports|July 27, 2017
Fragment optimization for GPCRs by molecular dynamics free energy calculations: Probing druggable subpockets of the A <sub>2A</sub> adenosine receptor binding sitePierre Matricon, Anirudh Ranganathan, Eugene Warnick, et al.
Pageof 60

Showing results (481-490 of 599) with videos related to

Sort By:
Pageof 60
Communications Biology|November 22, 2025
UDP-glucose and MRS2905 agonist-bound states of the purinergic P2Y<sub>14</sub> receptorJonathan F Fay, Joseph Kousouros, Zhan-Guo Gao, et al.
European Journal of Medicinal Chemistry|September 26, 2025
(N)-Methanocarba-adenosines as monoamine transporter allosteric inhibitors: Extended N<sup>6</sup> groups for bitopic stabilizationDilip K Tosh, Matteo Pavan, Laura B Kozell, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 12, 2004
Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cellsMeera Srivastava, Ofer Eidelman, Jian Zhang, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 5, 2010
Treatment of heart failure by a methanocarba derivative of adenosine monophosphate: implication for a role of cardiac purinergic P2X receptorsSi-Yuan Zhou, Mohammed Mamdani, Khaled Qanud, et al.
Journal of Medicinal Chemistry|June 23, 2016
Structure-Based Design of 3-(4-Aryl-1H-1,2,3-triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor AntagonistsAnna Junker, Ramachandran Balasubramanian, Antonella Ciancetta, et al.
Journal of Medicinal Chemistry|August 9, 2002
Synthesis, biological properties, and molecular modeling investigation of the first potent, selective, and water-soluble human A(3) adenosine receptor antagonistAnna Maconi, Giorgia Pastorin, Tatiana Da Ros, et al.
Molecular Pharmacology|September 18, 2009
Quantification of Gi-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of the human P2Y14 receptorRhonda L Carter, Ingrid P Fricks, Matthew O Barrett, et al.
Journal of the American Chemical Society|December 16, 2024
Photoswitchable Diazocine Derivative for Adenosine A<sub>3</sub> Receptor Activation in PsoriasisMarc López-Cano, Mirko Scortichini, Dilip K Tosh, et al.
Journal of Medicinal Chemistry|January 5, 2002
Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptorsHak Sung Kim, R Gnana Ravi, Victor E Marquez, et al.
Scientific Reports|July 27, 2017
Fragment optimization for GPCRs by molecular dynamics free energy calculations: Probing druggable subpockets of the A <sub>2A</sub> adenosine receptor binding sitePierre Matricon, Anirudh Ranganathan, Eugene Warnick, et al.
Pageof 60